Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Hematology | Musculoskeletal
 Disease Category: Leukemia
Location: United States, CA

Trial Information

SWOG S0805: Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) with or without Allogeneic Stem Cell Transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)

You are being asked to take part in this study because you have a certain type of acute lymphoblastic leukemia (ALL) where specific genes have been affected. The purpose of this study is to find out what effects, good and/or bad, the investigational drug dasatinib has on leukemia and on research participants with leukemia. You may remain on therapy for up to 5 years from the time you register, as long as you and your doctor feel that the therapy is helping you and your disease is not getting worse. You might be taken off of the therapy before the end of 5 years if your doctor feels it is best, but we would still like to follow you and your disease status. We would like to follow you for a total of 5 years from the time when you register for the study. During this follow-up period, you will be asked to visit your doctor every six months to receive a physical exam and blood tests. Your doctor may perform other tests at that time, if he/she believes that they are necessary.

Patient Inclusion/Exclusion Criteria:


- See http://clinicaltrials.coh.org for additional information.


City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)

View Map

Research Center Information: City of Hope

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.